Laborie Medical Technologies, a renowned medical technology company specializing in diagnostic and therapeutic devices, has made a strategic equity investment in Bright Uro, an innovative medical technology start-up. This investment serves as a testament to Laborie's commitment to advancing the field of urology and improving patient care. Bright Uro is focused on developing cutting-edge technologies for urologic imaging and minimally invasive procedures. Their core product, the Lumenci™ system, combines high-resolution imaging with advanced software algorithms to provide real-time visualization during endoscopic procedures. This technology aims to enhance the accuracy and efficiency of urologic interventions, ultimately leading to improved patient outcomes. By investing in Bright Uro, Laborie aims to leverage their expertise and resources to further develop and commercialize the Lumenci™ system. With its advanced imaging capabilities, the Lumenci™ system has the potential to revolutionize the field of urology by enabling precise diagnosis and targeted treatments. This strategic partnership not only benefits Bright Uro but also Laborie and its global customers. Laborie has a strong presence in the urology market, with a wide range of products and solutions used in the diagnosis and treatment of urologic conditions. By integrating Bright Uro's innovative technologies into their portfolio, Laborie can enhance their offerings and provide healthcare professionals with state-of-the-art tools to improve patient care. The investment in Bright Uro also aligns with Laborie's broader strategy of collaborating with dynamic and forward-thinking companies in the medical technology sector. By partnering with start-ups like Bright Uro, Laborie aims to foster innovation and drive advancements in the field of urology. Commenting on the investment, Brian Ellacott, CEO of Laborie, highlighted the shared vision between Laborie and Bright Uro. He stated, "We are excited to partner with Bright Uro and support the development of their groundbreaking technology. At Laborie, we are committed to improving patient outcomes and reshaping the future of urology. The Lumenci™ system aligns perfectly with our goals, and we look forward to working with Bright Uro to bring this innovative solution to healthcare providers worldwide." Laborie's investment in Bright Uro comes at a time when the demand for advanced urologic imaging and intervention technologies is growing significantly. Urologic conditions, such as prostate cancer, urinary incontinence, and kidney stones, affect millions of people globally, underscoring the need for innovative solutions to improve diagnosis and treatment. With Laborie's support, Bright Uro can accelerate the development and commercialization of the Lumenci™ system, making it available to healthcare providers and patients around the world. This collaboration has the potential to transform the field of urology and revolutionize the way urologic procedures are performed. Bright Uro is thrilled to have Laborie as a strategic investor and partner. Dr. Joel Vos, Founder and CEO of Bright Uro, expressed his enthusiasm, stating, "We are delighted to join forces with Laborie, a leader in the field of urology. With their vast experience and global reach, we can expand the adoption of our Lumenci™ system and make a significant impact on patient care. This partnership will drive innovation and enable us to bring our cutting-edge technology to healthcare professionals worldwide." Laborie's investment in Bright Uro represents their dedication to fostering innovation and advancing the field of urology. By collaborating with start-ups like Bright Uro, Laborie can stay at the forefront of medical technology, providing their customers with the latest advancements in urologic care. As the partnership between Laborie and Bright Uro progresses, the medical community can expect to see further advancements in urologic imaging and minimally invasive procedures. Through their combined expertise and resources, Laborie and Bright Uro aim to revolutionize the field of urology and improve patient outcomes worldwide.
top of page
bottom of page